Management of postoperative ileus: focus on alvimopan by Marderstein, Eric L & Delaney, Conor P
© 2008 Dove Medical Press Limited.   All rights reserved
Therapeutics and Clinical Risk Management 2008:4(5) 965–973 965
REVIEW
Management of postoperative ileus: focus
on alvimopan
Eric L Marderstein
Conor P Delaney
Division of Colorectal Surgery, 
Department of Surgery, University 
Hospitals Case Medical Center, Case 
Western, Reserve School of Medicine, 
Cleveland, Ohio, USA
Correspondence: Eric Marderstein
11100 Euclid Avenue, Lakeside 7th Floor, 
Cleveland, OH 44124, USA
Tel +1 216 844 7120
Fax +1 216 844 5957
Email eric.marderstein@uhhospitals.org
Abstract: Postoperative ileus (POI) is a transient loss of coordinated peristalsis precipitated 
by surgery and exacerbated by opioid pain medication. Ileus causes a variety of symptoms 
including bloating, pain, nausea, and vomiting, but particularly delays tolerance of oral diet and 
liquids. Thus POI is a primary determinant of hospital stay after surgery. ‘Fast-track’ recovery 
protocols, opioid sparing analgesia, and laparoscopic surgery reduce but do not eliminate 
postoperative ileus. Alvimopan is a mu opioid receptor antagonist that blocks the effects of 
opioids on the intestine, while not interfering with their centrally mediated analgesic effect. 
Several large randomized clinical trials have demonstrated that alvimopan accelerates the return 
of gastrointestinal function after surgery and subsequent hospital discharge by approximately 
20 hours after elective open segmental colectomy. However, it has not been tested in patients 
undergoing laparoscopic surgery and is less effective in patients receiving nonsteroidal anti-
inﬂ  ammatory agents in a narcotic sparing postoperative pain control regimen. Safety concerns 
seen with chronic low dose administration of alvimopan for opioid bowel dysfunction have not 
been noted with its acute use for POI.
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Introduction
Postoperative ileus (POI) is deﬁ  ned as a transient cessation of coordinated bowel 
motility after surgical intervention which prevents effective transit of intestinal 
contents or tolerance of oral intake (Delaney et al 2006). It is inevitable that some 
degree of ileus will accompany any surgical procedure but the duration is strongly 
inﬂ  uenced by the type, location, and duration of the surgical procedure and is often 
exacerbated by intraoperative and postoperative pain control medication. Intestinal 
surgery is most commonly associated with the development of ileus, likely related to 
mechanical manipulation of the intestine. This can be demonstrated experimentally 
in animals such that progressive increases in manipulation of the intestine at surgery 
results in prolonged postoperative intestinal transit times, more dyscoordination of 
intestinal contractions and increased production of inﬂ  ammatory mediators in the 
intestinal wall (Kalff et al 1998). Time to return of gastrointestinal function and the 
ability to tolerate an oral diet are of key importance in deﬁ  ning length of hospital stay, 
and patients are not discharged until they can independently maintain adequate oral 
nutrition. The costs of surgical care are generally divided into two major components: 
the cost of the operative procedure and the cost of postoperative care (Delaney et al 
2003). A major determinant of the cost of postoperative care is the length of hospital 
stay. As a result, interventions that can reduce the duration of POI reliably by one day 
reduce reduce hospital costs and improve bed availability. What frustrates clinicians is 
that although one can generally predict when a normal POI is likely to resolve, a certain 
fraction of patients develop a prolonged ileus that can unpredictably last many days 
longer, requiring parenteral nutrition, a nasogastric tube, and prolonged hospitalization. Therapeutics and Clinical Risk Management 2008:4(5) 966
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Although this can be secondary to a complication such as 
intrabdominal abscess, it can also occur with an obvious 
precipitating cause, termed primary POI.
Traditional postoperative care used to include the routine 
use of nasogastric drainage until documented evidence of 
return of gastrointestinal function was present, at which time 
a diet was gradually introduced. One lesson of the past two 
decades is that length of stay after abdominal surgery can 
be safely reduced with the use of ‘fast-track’ or ‘enhanced’ 
recovery protocols (Delaney et al 2001, 2003; Basse et al 
2004). Orogastric tubes are removed prior to extubation as 
their routine use during the postoperative period has consis-
tently been shown to be of no beneﬁ  t after abdominal surgery 
and increases discomfort (Vermeulen et al 2006). Patients are 
encouraged to ambulate early after surgery and several times 
daily thereafter (Waldhausen and Schirmer 1990) and are 
offered liquids as early as the evening of surgery. Analgesia 
is more carefully tailored and includes opiates supplemented 
with ketorolac, and even gabapentin to reduce susceptibility 
to pain. If oral ﬂ  uids are tolerated, patients are offered solid 
food prior to the return of bowel function. Patient-controlled 
analgesia (PCA) is switched to oral opioid analgesia on post-
operative day two if liquids are being tolerated. It has not been 
our practice to use epidural analgesia as a randomized trial 
comparing ‘fast-track’ recovery with PCA versus epidural 
analgesia offered no advantages (Zutshi et al 2005).
Laparoscopic surgery offers additional benefits in 
reducing POI. Reduced contact and manipulation of the 
bowel results in a decreased production of proinﬂ  ammatory 
cytokines that induce ileus (Delgado et al 2001). In addi-
tion, due to smaller incisions, postoperative opioid usage is 
decreased and the opioid-induced potentiation of POI is not 
as prominent. These differences routinely result in a decrease 
in length of stay from 1 to 2 days when randomized trials 
of open versus laparoscopic-assisted bowel resection are 
compared (Lacy et al 2002; Clinical Outcomes of Surgical 
Therapy Study Group 2004).
Postoperative analgesia with opioids
The mainstay of postoperative control of surgical pain is with 
the intravenous administration of morphine or other opioid 
class drugs, until they can be tolerated orally. Opioids are a 
double edged sword because although they provide excel-
lent relief of postoperative pain, they exacerbate the POI 
through their effects on the intestine. There are three types 
of opioid receptors (mu, delta, kappa) and they are present 
in both the central nervous system and the enteric nervous 
system, located in the myenteric and submucosal bowel 
plexus (Bohn and Raehal 2006). The majority of the effect of 
opioid receptor to slow intestinal transit comes from its direct 
effects in the enteric nervous system (Manara et al 1986). 
Most opioid analgesics exert their analgesic effects centrally 
via the mu opioid receptor, and their gastrointestinal effects 
are also mediated via the mu opioid receptor, but located in 
the intestine (Bohn and Raehal 2006).
A search for a compound that can block the detrimental 
effect of opioid at the enteric mu receptor while permitting 
its analgesic function at the central mu receptor yielded the 
candidate drugs alvimopan (Entereg®) and methylnaltrexone 
(Zimmerman et al 1994; Goodman et al 2007). Best studied 
of these compounds for its effects on POI is alvimopan, ini-
tially known as ADL 8-2698/LY 246736. Alvimopan is an 
orally administered peripherally acting mu opioid antagonist 
that does not cross the blood–brain barrier, thus not reversing 
opioid-induced analgesia. This compound has been studied 
for two major indications: 1) Acute administration to speed 
the recovery of gastrointestinal function after open abdominal 
surgery; 2) Chronic low dose administration to reverse the 
opioid-induced bowel dysfunction (OBD) and constipation 
from long-term opioid administration to control pain. The 
remainder of this article will focus on the clinical trials 
used to demonstrate the efﬁ  cacy and safety of alvimopan 
to speed the recovery of gastrointestinal function after open 
abdominal surgery.
Alvimopan postoperative ileus trials
Several randomized trials have been used to test the hypoth-
esis that alvimopan can reduce POI after laparotomy. 
While the trials differ in some respects they share many 
common features. The common features of the trials have 
created the beneﬁ  t of combined analysis without signiﬁ  cant 
heterogeneity in the populations.
Taguchi et al (2001) published the results of an initial 
study of 78 patients. This was a single institution random-
ized study of generally healthy patients having elective 
partial colectomy (n = 15) or total abdominal hysterectomy 
(n = 63) by open laparotomy, who were assigned to receive 
either placebo, 1 mg alvimopan or 6 mg alvimopan 2 hours 
prior to surgery then twice daily until the ﬁ  rst bowel move-
ment, discharge from the hospital, or for a maximum of 
7 days. Researchers assessing the patient outcomes and 
the patients were blinded to group assignment but it is not 
clear if the treating physicians were blinded in this study. 
Postoperative surgical management was not dictated by any 
speciﬁ  c protocol. Median time to passage of ﬁ  rst ﬂ  atus was 
signiﬁ  cantly decreased from 70 hours to 49 hours, time to Therapeutics and Clinical Risk Management 2008:4(5) 967
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ﬁ  rst bowel movement decreased from 111 to 70 hours and 
time until patients were ready for discharge decreased from 
91 to 68 hours when the placebo and 6 mg alvimopan groups 
were compared. Pain scores and narcotic usage were similar 
between groups, while the adverse effects nausea and vomit-
ing were signiﬁ  cantly less common in the 6 mg alvimopan 
group compared to placebo. The treatment effects were more 
pronounced in the 6 mg group than the 1 mg group versus 
placebo, but adverse events were not increased. Based on 
the results of this trial and other preliminary data, a series of 
multicenter randomized double blind trials was conducted 
with standardization of inclusion criteria, protocols, and 
outcome measures.
In March 2001, study 14CL302 (clinicaltrials.gov 
identiﬁ  er NCT003888258) began to enroll patients and the 
results were reported by Delaney et al (2005). This trial was 
a randomized, double-blind, placebo-controlled, phase III 
trial conducted at 40 centers throughout the US. Eligible 
patients were scheduled to undergo partial small or large 
bowel resection (except low anterior resection) or hyster-
ectomy and would receive either placebo, 6 mg alvimopan, 
or 12 mg alvimopan administered at least 2 hours before 
surgery and then twice daily until hospital discharge or a 
maximum of 7 postoperative days. Patients were excluded 
from participation if their procedure was a total colectomy 
or included an ileostomy or colostomy. Other exclusion 
criteria included concurrent severe medical problems, 
opioid use within 4 weeks of surgery, bowel obstruction 
or inﬂ  ammatory bowel disease. Patients were excluded if a 
nonsteroidal anti-inﬂ  ammatory drugs or epidural analgesia 
was planned. Postoperative care was dictated by a relatively 
fast-track protocol which included removal of nasogastric 
tubes at operation or the morning of postoperative day 
number one, early introduction of diet, and ambulation 
programs. Patient-controlled analgesia (PCA) was initially 
used for pain. The primary outcome measure was time to 
recovery of gastrointestinal function (GI-3) deﬁ  ned as the 
later of the following two events: time that the patient ﬁ  rst 
tolerated solid food (recovery of upper gastrointestinal func-
tion) and time that the patient ﬁ  rst passed ﬂ  atus or a bowel 
movement. Additional outcome measures included time to 
hospital discharge order and so called GI-2 deﬁ  ned as the 
later of the following two events: toleration of solid food and 
passage of a bowel movement. Modiﬁ  ed intention to treat 
analysis was applied to test for efﬁ  cacy. 451 patients were 
randomized into the 3 arms of the study with 15.8%–26.7% 
patients per group discontinuing treatment. Discontinuation 
of treatment due to adverse events was similar between 
the placebo and 12 mg group but lower in the 6 mg group, 
and protocol violations accounted for the majority of other 
treatment discontinuations. 67.5% of patients had bowel 
resection and 28.7% of patients had simple or radical hys-
terectomy. Mean time to gastrointestinal recovery (GI-3) 
was signiﬁ  cantly lower (86.2 hours) in the 6 mg alvimopan 
group compared with the placebo group (100.3 hours) but 
the decrease in the 12 mg alvimopan group (92.8 hours) 
only represented a trend. In subgroup analysis of this study, 
patients undergoing hysterectomy did not have a signiﬁ  cant 
decrease in their gastrointestinal recovery compared with 
placebo. More patients in the placebo group (20.7%) required 
6 or more days for return of bowel function compared with 
the 6 mg (12%) or 12 mg (13.1%) groups. Time to hospital 
discharge was decreased by 15 hours in patients treated with 
6 mg alvimopan and 14 hours for patients treated with 12 mg 
compared with placebo. Patients in the placebo and 6 mg 
alvimopan groups required the same amount of opioid pain 
medication while those in the 12 mg group required more, 
but pain scores did not differ between groups. Neither of the 
two deaths in the treatment arms of the study were believed 
to be caused by the medication.
In January 2002 study 14CL313 (clinicaltrials.gov 
identiﬁ  er NCT00388401) began to enroll patients and the 
results were reported by Wolff et al (2004). This also was 
a randomized, double-blind, placebo-controlled, parallel 
group study of 34 centers in the North America. Inclusion 
criteria, exclusion criteria, postoperative management and 
outcome measures were nearly identical to trial 14CL302 
except inflammatory bowel disease surgery and rectal 
surgery were permitted, and simple hysterectomy was 
excluded. The intention to treat population in this study 
was 469 patients and the most common operation was colon 
resection (84%) followed by small bowel resection (12%) 
and radical hysterectomy (4%). In this study, return of 
gastrointestinal function (GI-3) was signiﬁ  cantly shortened 
by 15 hours in the 6 mg alvimopan group and 22 hours in 
the 12 mg alvimopan group compared with placebo. GI-2 
was signiﬁ  cantly faster in both treatment groups and hos-
pital discharge was earlier by 13 hours in the 6 mg group 
and 20 hours in the 12 mg group compared with placebo 
patients. Patients in the 12 mg alvimopan group used the 
same amount of narcotics as the placebo group, but there 
were more narcotics used by the 6 mg group. Pain scores 
were not different among groups. Statistically fewer patients 
required nasogastric tube placement in the 12 mg alvimopan 
group (4.8%) compared with placebo (14.8%). Adverse 
events were similar between groups.Therapeutics and Clinical Risk Management 2008:4(5) 968
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In December 2001, study 14CL308 (clinicaltrials.gov 
identiﬁ  er NCT00388479) was started and the results were 
reported by Viscusi et al (2006). This trial was similar 
in design and administration to the previous two trials 
(14CL302 and 14CL313) and over 600 patients were random-
ized between the three arms (placebo, 6 mg alvimopan and 
12 mg alvimopan). In the initial analysis alvimopan did not 
signiﬁ  cantly accelerate recovery of gastrointestinal function. 
However, when an analysis that controlled for the covariates 
sex and operative duration, alvimopan 6 mg was found to 
speed gastrointestinal recovery by 7.5 hours and alvimopan 
12 mg speeded recovery by 9.9 hours compared to placebo. 
Male sex and longer operative duration were associated with 
longer times for return of bowel function. Faster GI-2 and 
shorter times to discharge were also seen with both alvimopan 
groups when controlled for these confounding variables. Pain 
scores, opioid usage, and adverse events did not differ.
A pooled analysis analysis of these three trials (14CL302, 
14CL308 and 14CL313) was performed by Delaney et al 
(2007). One advantage of the similarities in trial design 
is that concerns about heterogeneity of patients in pooling 
the results are minimal. For this analysis, the 1212 patients 
in the three trials undergoing bowel resection were compared. 
The pooled results were signiﬁ  cant and universally favor-
able in that both the 6 mg and 12 mg dosing of alvimopan 
resulted in a faster return of gastrointestinal recovery (GI-3; 
12.4 and 14.8 hours, respectively), faster time to bowel 
movement (GI-2; 15 and 18.3 hours, respectively), and 
discharge orders written (16 and 18.4 hours, respectively). 
Postoperative ileus, nasogastric tube insertion and hospital 
readmission were all lower for both alvimopan groups versus 
placebo. There were no differences in adverse events, opioid 
usage or pain scores.
In June 2004 the additional study 14CL314 (clinicaltrials.
gov identiﬁ  er NCT00205842) was started and has since 
been completed (Trial identiﬁ  er NCT00205842 at www.
clinicaltrials.gov). The results have been used in published 
analysis of aggregate trial results, but to date have only been 
independently published in poster form and not as an a full 
length manuscript (Ludwig et al 2006). The study has some 
differences from the three that preceded it. Only patients 
having a small or large bowel resection by open laparotomy 
were eligible, no longer including any patients having a 
hysterectomy. While the study consisted of a placebo, 6 mg 
and 12 mg arm, the drug is dosed from 30–90 minutes prior 
to surgery as opposed to at least 2 hours in previous studies. 
Additional exclusion criteria include patients with a history of 
gastrectomy, short bowel syndrome or multiple previous open 
abdominal surgeries. Outcome measures and deﬁ  nitions were 
not changed, and results were similar to those noted in previ-
ous trials and in the previously described pooled analyses.
To address the issue of the safety and efficacy of 
alvimopan in speeding the return of gastrointestinal function 
after hysterectomy, a separate trial was devised and the results 
reported by Herzog et al (2006). In this trial, 519 women were 
randomized 4:1 to receive either alvimopan 12 mg or placebo 
2 hours before hysterectomy by laparotomy and had treatment 
continued for 7 days postoperatively. One major difference 
was that patients would continue taking the drug/placebo at 
home for a total of 7 days if discharged, which most of them 
were. The rationale for this was that the average length of 
stay for hysterectomy was short and many patients appeared 
as censored observations – they did not meet the endpoint 
(return of bowel function) prior to discharge from the hospital 
and completion of the study. Patients kept journals at home 
regarding their symptoms and bowel functions. Adverse 
events, opioid usage, and pain scores were no different 
between groups. Recovery of gastrointestinal function 
(GI-3), toleration of solid food, or hospital discharge times 
were not different between groups. Mean time to ﬁ  rst bowel 
movement was faster in the alvimopan group by 20.2 hours. 
Laxative use was higher in the placebo group and a larger 
percentage of the alvimopan-treated patients were ambula-
tory for more than an hour a day.
GSK001 was a study similar to the four previous North 
American studies but was instead a multicenter European 
trial. The results were published by Büchler et al (2008). It 
was a randomized, double-blind, placebo controlled, parallel 
group study involving over 900 patients at 70 hospitals in 
11 countries in Europe and elsewhere. Initially the inclusion 
criteria were similar to the previous North American studies 
in that patients undergoing small or large bowel resection or 
hysterectomy by laparotomy were eligible. This was modiﬁ  ed 
to include only patients having bowel resection on the basis 
of data analyzed from the North American studies. Patients 
were randomized to receive either placebo, 6 mg alvimopan 
or 12 mg alvimopan 2 hours before surgery and twice daily 
after to a maximum course of 7 days. A notable difference in 
postoperative care protocols from previous trials permitted 
the use of nonsteroidal anti-inflammatory medications 
which ended up being used in 69% of   patients. In addi-
tion, use of   PCA was not required and was only present in 
45% of patients. The remainder of patients had some form 
of nurse-administered opioid pain control. The primary 
outcome measure was mean time to return of gastrointestinal 
function (GI-3) which was reduced by 8.5 hours in the 6 mg Therapeutics and Clinical Risk Management 2008:4(5) 969
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alvimopan group and 4.8 hours in the 12 mg alvimopan group 
compared to placebo. When using the Hochberg correction 
for multiple comparisons, both results were not found to be 
statistically signiﬁ  cant. Mean time to toleration of solid food 
and ﬁ  rst bowel movement (GI-3) was signiﬁ  cantly decreased 
by 14.3 hours in the 6 mg alvimopan groups and 10.7 hours in 
the 12 mg alvimopan group compared with placebo. Patients in 
the PCA group received more opioid than the non-PCA groups, 
although pain scores did not differ. In the PCA subgroup of 
patients, time to return of gastrointestinal function (GI-3) was 
decreased in both the 6 mg alvimopan and 12 mg alvimopan 
group. Adverse events were not different between groups.
Senagore et al (2007) published the pooled data analysis 
from the four North American trials (14CL302, 14CL308, 
14CL313, 14CL314) and the one European trial (GSK001). 
The subgroup analyzed were patients undergoing bowel 
resection and either receiving placebo or 12 mg alvimopan 
by the previously described dosing schedule. The baseline 
characteristics are summarized in Table 1. One interest-
ing observation was that patients aged over 65 years, male 
patients, and nonwhite patients had a signiﬁ  cantly longer time 
to return of gastrointestinal function (GI-3) while the time to 
ﬁ  rst bowel movement (GI-2) showed a similar trend but was 
not signiﬁ  cant. Alvimopan speeded GI-3, GI-2, and time to 
hospital discharge in the pooled analysis and in subgroups of 
patients regardless of gender, age, or ethnicity, as demonstrated 
in Figure 1. These beneﬁ  cial effects of alvimopan versus 
placebo were preserved in groups receiving perioperative 
antibiotics, mechanical bowel preparation, histamine receptor 
antagonists, and proton pump inhibitors. These were speciﬁ  -
cally noted because these interventions have been associated 
with lower effective level of drug doses in practice (Foss 
et al 2008). No adverse events were more common among 
the pooled alvimopan groups compared to placebo but the 
adverse events nausea, vomiting, or POI were more common 
in patients receiving placebo, as shown in Table 2.
An independent group of surgical researchers with 
experience in meta-analysis techniques analyzed the series 
of alvimopan trials (Tan et al 2006). The ﬁ  ve studies meeting 
their criteria included the ﬁ  rst three North American trials 
(14CL302, 14CL308 and 14CL313) in additional to the 
trial on hysterectomy patients reported by Herzog et al 
(2006) and the single center study published by Taguchi 
et al (2001) and included over 2000 patients. The authors 
believed this to be a good subject for pooled analysis because 
of minimal heterogeneity in the studies and their ﬁ  nding 
of only small variation in the hazard ratios for return of 
bowel function to indicate that the studies are suitable for 
pooling data. Their conclusion was that gastrointestinal 
recovery (GI-3), time to ﬁ  rst bowel movement (GI-2), and 
Table I Patient demographics and baseline characteristics for patients undergoing bowel resection in phase III trials (modiﬁ  ed-intent-to-treat 
population). Reproduced with permission from Senagore A, Bauer J, Du W, et al 2007.   Alvimopan accelerates gastrointestinal recovery after 
bowel resection regardless of age, gender, race or concomitant medication use. Surgery, 142:478–86. Copyright © 2007 Mosby, Inc
14CL302 
(N = 197) 
14CL308 
(N = 281) 
14CL313 
(N = 302) 
GSK001 
(N = 468) 
14CL314 
(N = 629) 
Overall 
(N = 1877) 
Age (y) 
Mean ± SD 61.7  ± 12.8  60.5 ± 15.5 61.4  ± 14.6  63.9 ± 12.6  59.8 ± 14.1 61.4  ± 14.0 
65, n (%) 83 (42.1)  125 (44.5)  144 (47.7)  246 (52.6)  247 (39.3)  845 (45.0) 
75, n (%) 37 (18.8)  53 (18.9)  58 (19.2)  96 (20.5)  91 (14.5)  335 (17.8) 
Race, n (%)
White  169 (85.8)  223 (79.4)  267 (88.4)  462 (98.7)  529 (84.1)  1,650 (87.9) 
Nonwhite  28 (14.2)  58 (20.6)  35 (11.6)  (1.3)  100 (15.9)  227 (12.1) 
Gender, n (%)
Female  108 (54.8)  137 (48.8)  155 (51.3)  210 (44.9)  320 (50.9)  930 (49.5) 
BMI 
Mean ± SD, kg/m2 28.2  ± 5.8  27.5 ± 6.2  27.8 ± 5.9 26.5  ± 4.5 28.4  ± 6.3 27.7  ± 5.8 
30 kg/m2, n (%) 68 (34.5)  73 (26.0)  83 (27.5)  83 (17.7)  210 (33.4)  517 (27.5) 
Surgery type, n (%)
Small BR  – 27 (9.6)  35 (11.6)  21 (4.5)  53 (8.4)  136 (7.2) 
Large BR  197 (100.0)  254 (90.4)  267 (88.4)  447 (95.5)  576 (91.6)  1,741 (92.8) 
Surgery duration (h) 
Overall mean ± SD 
2.0 ± 1.0 2.5  ± 1.2 2.1  ± 1.1 2.6  ± 1.1 2.0  ± 1.1 2.2  ± 1.1 
Abbreviations: BMI, body mass index; BR, bowel resection; SD, standard deviation. Therapeutics and Clinical Risk Management 2008:4(5) 970
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time to discharge order were faster, whereas postoperative 
narcotic usage, pain scores, and adverse events were no dif-
ferent when 12 mg alvimopan was compared with placebo.
The Cochrane Collaboration has recently analyzed the 
topic of the efﬁ  cacy and safety of pharmacologic treatment 
of adynamic ileus after abdominal surgery (Traut et al 2008). 
14 different pharmacologic treatments were evaluated, 
including alvimopan. The overall quality of the studies 
was judged to be moderate, deﬁ  ciencies in methodology or 
reporting of the randomization and blinding process being 
cited as deﬁ  ciencies. In discussion with some of the study 
investigators, this observation is a reporting deﬁ  ciency, as 
randomization and blinding in the trials were performed 
according to accepted convention. Lastly, the facts that 
the studies had received funding from the pharmaceutical 
company responsible for developing the compound and that 
some coauthors were employees of the company were noted. 
Despite this, they did acknowledge that alvimopan may be 
likely to reduce the time to recovery of bowel function after 
major abdominal surgery.
Safety
In the POI trials, alvimopan was judged to be very safe with 
no difference in adverse event rates from placebo (Senagore 
A
B
P value*
Overall
< 65 years old
≥ 65 years old
≥ 75 years old
Age
Sex
Race
Male
White
Nonwhite
Female
Demographic subgroup
Overall
< 65 years old
 65 years old
≥ 75 years old
Age
Sex
Race
Male
White
Nonwhite
Female
Demographic subgroup
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.014
P value*
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.036
1.44
1.44
1.45
1.44
1.42
1.42
1.57
1.43
0 0.5 1.0 1.5 2.0
0 0.5 1.0 1.5 2.0
In favor of placebo
In favor of placebo
1.32
1.30
1.34
1.46
1.41
1.24
1.32
1.34
≥
In favor of alvimopan
In favor of alvimopan
< 0.001
Figure 1 Alvimopan 12-mg treatment effect on time to gastrointestinal recovery within demographic subgroups: Hazard ratios for time to GI-2 (A) and GI-3 (B) recovery. 
GI-2, time to ﬁ  rst toleration of solid food and time to ﬁ  rst bowel movement; GI-3, time to ﬁ  rst toleration of solid food and time to ﬁ  rst bowel movement or ﬂ  atus. *P values 
compare alvimopan 12 mg versus placebo within subgroups.  Reproduced with permission from Senagore A, Bauer J, Du W, et al 2007.   Alvimopan accelerates gastrointestinal 
recovery after bowel resection regardless of age, gender, race or concomitant medication use. Surgery, 142:478–86. Copyright © 2007 Mosby, Inc.Therapeutics and Clinical Risk Management 2008:4(5) 971
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et al 2007). As expected, the most common adverse events 
in the trials were nausea and vomiting, but these were less 
common in the alvimopan-treated groups. The pooled data 
do not raise any safety concerns regarding cardiovascular 
events, neoplasms, or fractures.
The primary concern about the safety of alvimopan was 
derived from the adverse event proﬁ  les of randomized trials 
of alvimopan to reduce the symptoms of OBD. In one study, 
patients were treated with a low dose of alvimopan (0.5 mg 
twice a day) for a 12-month period. In this study, there were 
more cardiac-related adverse events such as myocardial 
infarction in the 538-patient treatment arm compared to the 
267 placebo patients, but it was not signiﬁ  cant (http://www.
fda.gov/ohrms/dockets/ac/08/slides/2008-4336s1-04-Adolor-
Mortensen.pdf ). When these data were pooled with several 
similar studies of alvimopan in OBD, the trend is less striking. 
In this same study, neoplasms tended to be more common in 
the alvimopan-treated group but this also did not reach sta-
tistical signiﬁ  cance. In studies speciﬁ  cally with cancer pain, 
a trend towards increased number of deaths in the alvimopan 
group was noted, but the studies were not controlled for factors 
known to favor disease progression. In multivariate analysis, 
alvimopan was not found to be a signiﬁ  cant predictor for risk 
of death. Lastly fractures seemed to be more common in the 
alvimopan-treated group in these studies but total numbers 
of events were small.
Regulatory approval
In May 2008, the Food and Drug Administration (FDA) 
concluded a series of hearings on the efﬁ  cacy and safety 
of alvimopan in the treatment of POI, and approved its use 
(Press release May 20, 2008). The drug was approved with 
a Risk Evaluation and Mitigation Strategy (REMS) for 
continued monitoring and to ensure that the beneﬁ  ts of the 
drug outweigh the risks. The approved indication was for 
a 12 mg dose to be administered preoperatively to patients 
scheduled to undergo small or large bowel obstruction by 
open laparotomy. The treatment can continue twice daily for 
a total of 7 days, but can be administered only in the hospi-
tal and is not approved for use on outpatients. In addition, 
hospitals must be specially certiﬁ  ed to dispense the drug and 
educational materials must be given to health care workers. 
Efﬁ  cacy data was examined from the POI trials and safety 
data was used from all trials including long-term low dose 
trials to treat opioid induced constipation.
Comment
Randomized surgical trials are difﬁ  cult to control and expen-
sive to complete. Despite their obvious ﬁ  nancial interest 
in success of alvimopan, Aldolor and GlaxoSmithKline 
should be commended for their commitment to an academic 
approach to the study of the safety and efﬁ  cacy of this drug. 
Even pooled analysis of the placebo groups from their trials 
have been used to gain a better understanding of what is 
normal recovery from open gastrointestinal surgery (Wolff 
et al 2007). The homogeneity of the trials and data make a 
strong case that alvimopan 12 mg twice a day will decrease 
the time to return of gastrointestinal function and thus hos-
pital discharge by roughly 12 hours in patients having open 
segmental bowel resection. Unfortunately, these trials are 
Table 2   Treatment-emergent adverse events reported in 5% of patients undergoing bowel resection. Reproduced with permission 
from Senagore A, Bauer J, Du W, et al 2007.   Alvimopan accelerates gastrointestinal recovery after bowel resection regardless of age, 
gender, race or concomitant medication use. Surgery, 142:478–86. Copyright © 2007 Mosby, Inc
Patients, n (%) 
North American trials*  European trial† 
Adverse event  Placebo
(n = 695)
Alvimopan 12 mg 
(n = 714)
Placebo
(n = 292)
Alvimopan 12 mg 
(n = 297)
Nausea 454  (65.3)  399  (55.9)‡ 21 (7)  28 (9) 
Vomiting 188  (27.1)  134  (18.8)‡ 21 (7)  13 (4) 
Abdominal distension  127 (18.3)  110 (15.4)  NR  NR 
Pyrexia  122 (17.6)  88 (12.3)  17 (6)  16 (5) 
POI 107  (15.4)  57  (8.0)‡ NR NR 
Hypertension  101 (14.5)  100 (14.0)  14 (5)  19 (6) 
Postoperative wound infection 66 (9.5)  48 (6.7)  11 (4)  14 (5) 
POI, postoperative ileus; NR, not reported.
*Based on pooled modiﬁ  ed intent-to-treat population. 
†Based on safety population. 
‡P  0.001; P-values calculated using Fisher’s exact test. Therapeutics and Clinical Risk Management 2008:4(5) 972
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chasing after the moving target of advances in perioperative 
surgical care. Nonsteroidal anti-inﬂ  ammatory agents are now 
used in most ‘fast-track’ recovery protocols as they have a 
narcotic sparing effect. When these drugs were permitted in 
the European trial of alvimopan, the treatment effect was less 
robust, particularly in patients who were not using a PCA 
and had lower opiate doses after surgery. Furthermore, an 
increasing percentage of bowel resections in patients with-
out prior surgery are now performed laparoscopically with 
decreased use of narcotic pain medicine and reduced length 
of stay (Delaney et al 2008). To date, there are no clinical 
trial data for the use of alvimopan in laparoscopic surgery 
patients, and with the lower opiate doses required, it is cur-
rently unclear whether a beneﬁ  t will be noted.
Issues with safety noted in the chronic OBD population 
are undergoing further analysis. Almost all events were noted 
in a single trial, and likely related to vagaries of this trial 
alone. No such events have been substantiated in the more 
than 2000 patients receiving short acute course for POI.
Despite these shortcomings, an 18-hour acceleration of 
gastrointestinal recovery, with consequent decrease in length 
of stay may have the ability to reduce hospital stay by three 
days for every two intestinal resectional surgery patients. 
This has the potential to save signiﬁ  cant health care dollars, 
depending on the cost of administration of the drug, and also 
increase bed availability by getting patients home earlier. In 
addition, the hysterectomy trial outpatient data indicated that 
patients who received alvimopan had a more durable and 
symptom-free bowel function during the early days of their 
recovery at home and this beneﬁ  t has value. Continued usage 
and monitoring will alleviate safety concerns.
What may be even more important is that alvimopan 
may allow more predictable recovery of gastrointestinal 
function, and more predictable discharge. One of the ﬁ  nd-
ings noted in many studies was that the number of patients 
with prolonged recovery (hospital stay greater than 7 days) 
was signiﬁ  cantly reduced with alvimopan. The number of 
readmissions was also reduced by 50% in some trials (Wolff 
et al 2004). As prolonged stay and readmission are two of 
the major adverse events related to major bowel surgery, 
and certainly two of the primary outcomes that reduce our 
ability to standardize care, alvimopan may permit surgeons 
and hospitals to improve the overall quality and efﬁ  ciency 
of care they provide.
Finally, alvimopan is currently alone, in that there 
are no other medications that have been shown with this 
degree of scientiﬁ  c rigor to be effective in speeding the 
return in gastrointestinal function after abdominal surgery. 
Having recently been FDA approved, it appears to have 
robust efﬁ  cacy and safety data, showing clinical beneﬁ  t 
in patients undergoing segmental small or large bowel 
resection by laparotomy who are planned to have PCA. 
Cost of the medication will now determine how it can be 
integrated into hospital care pathways. Future studies will 
need to address cost-effectiveness in practice and perhaps 
more important, the beneﬁ  t of alvimopan in those having 
laparoscopic intestinal surgery.
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